Read by QxMD icon Read

Her 2 positive Breast cancer

J J Zhu, D C Jiao, J H Qiao, L N Wang, Y Z Ma, Z D Lu, Z Z Liu
Objective: To explore the expression of androgen receptor (AR) in the tissues as well as its association with the clinicopathological factors of primary breast cancer patients treated with neoadjuvant chemotherapy (NAC), and analyze the effect of AR in the prediction of pathologic complete response (PCR) rate. Method: A total of 668 breast cancer patients treated with NAC in Henan Cancer Hospital between March 2014 and June 2017 were retrospectively reviewed. The relationship of AR expression and clinicopathological characteristics was calculated using chi square test...
February 27, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
Shabaz Majid, Lisa Rydén, Jonas Manjer
BACKGROUND: Axillary lymph node status is one of the most important prognostic factors for breast cancer. The aim of this study was to determine predictive factors for metastasis to sentinel node (SN) in primary invasive breast cancer. METHOD: This is a study of 3979 patients with primary breast cancer during 2008-2013 in Malmö and Lund scheduled for surgery and included in the information retrieved from Information Network for Cancer Care (INCA). The final study population included 2552 patients with primary invasive breast cancer...
March 12, 2018: World Journal of Surgical Oncology
Shagufta Naeem, Shabana Naz, Anila Riyaz, Fouzia Jehangir, Naeema Afzal
BACKGROUND: Breast cancer is the second most common cancer in females including Pakistan. Nowadays immunohistochemistry has revolutionized management of breast cancer. In this study, we determined the frequency of various subtypes of breast cancer on the basis of immunohistochemical staining and their correlation with ki 67 index. METHODS: Fifty consecutive diagnosed breast cancers cases received during the period February 2014 to February 2016, at Ayub Medical College, Pathology Department were included in this cross-sectional study...
January 2018: Journal of Ayub Medical College, Abbottabad: JAMC
Yuan-Chiang Chung, Ching-Ming Chang, Wan-Chen Wei, Ting-Wei Chang, King-Jen Chang, Wei-Ting Chao
Trastuzumab emtansine (T-DM1) is an antibody drug conjugate (ADC) that was recently approved for the treatment of HER-2-positive metastatic breast cancer. The drug sensitivity of ADCs depends mainly on the internalization efficiency of the drug. Caveolin-1 was shown to promote T-DM1 internalization and enhance drug sensitivity. Whether caveolin-1 can be overexpressed to improve T-DM1 efficacy is interesting and has the potential for clinical application. In this study, diabetes drug metformin was investigated in terms of induction of caveolin-1 expression for increased efficacy of subsequent T-DM1 application...
March 2, 2018: Scientific Reports
Monica Zuradelli, Giovanna Masci, Emanuela Ferraro, Agnese Losurdo, Rita De Sanctis, Rosalba Torrisi, Armando Santoro
RATIONALE: Breast cancer is the most common cancer affecting females worldwide and its lifetime risk increases with age. Human epidermal growth factor receptor gene-2 (HER-2) positive breast cancer represents about 20% of all breast cancers, 1 out of 10 is diagnosed in women over 70 years of age. It tends to be more aggressive and to spread more quickly than other subtypes, but the introduction in clinical practice of new anti-HER-2 agents combined with chemotherapy has significantly improved progression free and overall survival...
March 2018: Medicine (Baltimore)
Olaronke Oshilaja, Nomani Laila, Benjamin C Calhoun, Alberto J Montero, Charles D Sturgis
Mammary ductal carcinoma in situ (DCIS) is classically treated by combinations of excision, radiation, and endocrine therapy, based upon the specific needs of individual patients. Estrogen receptor (ER) status is generally assessed by immunohistochemistry (IHC) in newly diagnosed cases of DCIS, and endocrine therapy in this setting is thought to be chemopreventive. The potential impact of androgens on mammary carcinogenesis has been studied in recent years, and several authors have proposed androgen receptor (AR) IHC testing and targeted antiandrogenic therapy in patients with locally advanced or metastatic triple-negative invasive breast cancer (ie, negative for ER and progesterone receptor and HER-2)...
February 27, 2018: Applied Immunohistochemistry & Molecular Morphology: AIMM
Dongmo Wang, Kai Zhu, Jiawei Tian, Ziyao Li, Guoqing Du, Qiang Guo, Tong Wu, Juan Li
The purpose of this study was to analyze the clinicopathological and ultrasound characteristics of triple-negative breast cancers (TNBCs) and compare these findings with those for hormone receptor-positive (HR-positive)/human epidermal growth factor receptor-2-negative (HER-2-negative) tumors. Seventy-five TNBCs and 135 HR-positive/HER-2-negative breast cancers were reviewed. Data from conventional ultrasound, Doppler vascularity and elastography were included in the analysis. TNBCs had a higher histologic grade and Ki-67 level...
February 23, 2018: Ultrasound in Medicine & Biology
Li-Feng Dong, Shu-Ying Xu, Jing-Pei Long, Fang Wan, Yi-Ding Chen
Objective The aim of the present study was to determine how many sentinel lymph nodes (SLNs) are appropriate for predicting non-SLN metastasis in breast cancer. Methods The association between clinicopathological features and non-SLN metastasis was retrospectively analyzed in 472 patients who underwent axillary lymph node dissection (ALND) following SLN biopsy. Another 251 patients who underwent only SLN biopsy without ALND were analyzed and followed up for 2 years. Results A large tumor size, positive SLN, and HER-2 positivity were independent predictors of non-SLN metastasis...
February 2018: Journal of International Medical Research
Min Fang, Li Zhu, Hengyu Li, Xizhou Li, Yanmei Wu, Kainan Wu, Jian Lin, Yuan Sheng, Yue Yu
The database of BRCA1/2 mutations in Chinese population remains incomplete at present. Therefore, the present study aimed to report specific harmful BRCA1/2 mutations in the Chinese population and discuss the clinicopathological features in mutation carriers. BRCA1/2 germline mutation tests for 71 patients with breast cancer from a hereditarily high-risk Chinese population were performed using next-generation sequencing for identification of deleterious mutations. Furthermore, the clinicopathological features between BRCA1/2 mutation carriers and non-carriers were compared...
March 2018: Oncology Letters
Chang Y Park, Niall C McGonigle
There are numerous surgical approaches for the treatment of pericardial effusions but no clear consensus of best management. We present a 44-year-old woman with metastatic breast cancer presenting with a new 2-cm pericardial effusion on ultrasound. In light of the patient's palliative condition and the urgent need for chemotherapy, careful consideration was made for her surgical drainage of the pericardial effusion. Because of the patient's medical comorbidities, a general anesthetic was deemed not to be in the patient's best interest...
February 9, 2018: Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery
Moushumi Suryavanshi, Anurag Mehta, Jiten Jaipuria, Dushyant Kumar, Gayatri Vishwakarma, Manoj Kumar Panigrahi, Haristuti Verma, Mumtaz Saifi, Sanjeev Sharma, Simran Tandon, D C Doval, Bhudev C Das
BACKGROUND: IHC and FISH are used for categorizing HER 2 status in breast cancer at the protein and DNA level, respectively. HER 2 expression at the RNA level is quantitative, cheaper, easier to standardize and free from interobserver variation. METHODS: 115 consecutive patients were tested by IHC, FISH and RT-PCR (test cohort). Assuming FISH result to be the response variable, ROC curves for RT-PCR ratio were analyzed to label HER 2 negative, equivocal and positive cases as RT-PCR score 1, 2 and 3, respectively...
February 9, 2018: Breast Cancer: the Journal of the Japanese Breast Cancer Society
Sandi Shen, Gaofang Xiao, Richang Du, Ningdong Hu, Xu Xia, Haibo Zhou
This study aimed to evaluate correlations between lymphovascular invasion (LVI) and the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER-2), Ki-67, CK5/6, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), E-cadherin, BCL11A and P53 in invasive breast cancer and to identify predictors of LVI based on these pathological factors. In all, 392 paraffin-embedded tissues from consecutive patients with primary operable invasive breast cancer were included...
January 5, 2018: Oncotarget
Zhang Xiping, Chen Bo, Yang Shifeng, Yu Feijiang, Yang Hongjian, Cheng Qihui, Tang Binbin
Background: As a type of new targets for prognosis of malignancies, long non-coding RNA MALAT1 (metastasis-associated lung adenocarcinoma transcription 1) is associated with proliferation and metastatic abilities of several malignancies. However, its relations to development and migration of triple negative and human epidermal growth factor receptor 2 (Her-2) positive breast cancers haven't been reported. Objectives: In this paper, we aimed to discuss how MALAT1 is connected with and affects proliferation and invasion abilities of cells in Her-2 positive and triple-negative breast cancers (TNBC)...
January 5, 2018: Oncotarget
Rabeb Ghali, Maryam A Al-Mutawa, Abrar K Al-Ansari, Sonia Zaied, Hanen Bhiri, Touhami Mahjoub, Wassim Y Almawi
BACKGROUND: Estrogen is key to breast cancer pathogenesis, and acts by binding its receptor (ER), which exists as ERα and ERβ, encoded by ESR1 and ESR2 genes, respectively. Studies that investigated the association of ESR1 and ESR2 variants with breast cancer yielded mixed outcome, and ethnic contribution was proposed. We evaluated the association between ESR1 and ESR2 variants and breast cancer and associated features in Tunisian women. METHODS: Retrospective case-control study involving 207 female breast cancer patients, and 284 control women...
February 4, 2018: Gene
Katsunori Narahara, Tomomi Abe, Kenji Katsumata, Akihiko Tsuchida
A 79-year-old woman presented with a chief complaint of a palpated tumor on her right axilla. The right breast tumor size was 18mm and the axillary lymph node size was 30 mm, as detected with ultrasonography. Pathological findings indicated the presence of an ER(-), Pg R(-), HER2-negative apocrine carcinoma. The presence of axillary lymph node metastasis was diagnosed from the apocrine carcinoma. Eribulin(1.5mg)was administered 3 times before surgery. Tumors were significantly reduced. The Bt+Ax(Patey procedure)dissection was performed until Level 2...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Yasuhiro Toyoda, Shigeyuki Hojo, Setsuko Yoshioka, Toshiki Noma, Hiroki Matsunaga, Hiromichi Miyagaki, Hisashi Nishida, Tatsushi Shingai, Osamu Takayama, Takayuki Fukuzaki, Hiroaki Ohigashi, Yoshiichi Maeura, Motomu Tsuji
A 39-year-old woman with very sever obesity was admitted to our hospital for a right breast redness and hardness. Her height, weight and BMI were 166 cm, 145 kg and 52.6 kg/m2. Her breast had peau d'orange. CT scan showed swelling of whole right breast and Level I , II lymph node. We performed core needle biopsy and diagnosed as the inflammatory breast cancer with ER and HER2 positive. We introduced chemotherapy(pertuzumab, trastuzumab and paclitaxel)and nutrition counseling in order to reduce her body weight...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Ruixin Xu, Jianbin Li, Yingjie Zhang, Hongbiao Jing, Youzhe Zhu
RATIONALE: Occult breast cancer (OBC) is extremely rare in males with neither symptoms in the breast nor abnormalities upon imaging examination. PATIENT CONCERNS: This current case report presents a young male patient who was diagnosed with male OBC first manifesting as axillary lymph node metastasis. The physical and imaging examination showed no primary lesions in either breasts or in other organs. DIAGNOSES: The pathological results revealed infiltrating ductal carcinoma in the axillary lymph nodes...
December 2017: Medicine (Baltimore)
Luca Cantini, Mirco Pistelli, Agnese Savini, Lucia Bastianelli, Arianna Della Mora, Filippo Merloni, Michela Burattini, Rossana Berardi
Since the introduction of targeted therapies, prognosis in human epidermal growth factor receptor (HER) 2-positive metastatic breast cancer (MBC) has radically changed. The addition of Pertuzumab to Trastuzumab and standard chemotherapy has further increased patients' overall survival (OS). However, there is no agreement regarding the optimal duration of trastuzumab therapy in selected patients achieving long-term complete remission. In addition, no potential factors of long-term benefit have been identified yet...
January 2018: Molecular and Clinical Oncology
Henry Wc Leung, Agnes Lf Chan, Shyh-Yau Wang
Objectives To model the cost-utility of trastuzumab combined with docetaxel for patients with HER-2 positive metastatic breast cancer (mBC) without prior other chemotherapy. Methods A Markov cohort simulation was used to model the cost-utility of trastuumab combined with docetaxel (TD) for women with HER-2 positive metastatic breast cancer without prior chemotherapy from the perspective of Taiwan National Health Service (NHS). The clinical and economic data were retrieved directly from the Catastrophic Illness Patient Databases (CIPD)...
January 1, 2018: Journal of Oncology Pharmacy Practice
Hossein Bakhtou, Asiie Olfatbakhsh, Abdolkhaegh Deezagi, Ghasem Ahangari
BACKGROUND: Breast cancer is one of the common causes of mortality for women in Iran and other parts of the world. The substantial increasing rate of breast cancer in both developed and developing countries warns the scientists to provide more preventive steps and therapeutic measures. This study is conducted to investigate the impact of neurotransmitters (e.g., Dopamine) through their receptors and the importance of cancers via damaging immune system. It also evaluates dopamine receptors gene expression in the women with breast cancer at stages II or III and dopamine receptor D2 (DRD2) related agonist and antagonist drug effects on human breast cancer cells, including MCF-7 and SKBR-3...
January 29, 2018: Current Drug Discovery Technologies
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"